% | $
Quotes you view appear here for quick access.

Valeant Pharmaceuticals International, Inc. Message Board

  • gerthagertha gerthagertha Dec 7, 2012 3:52 PM Flag

    VRX overvalued & has the rank 8.1...


    Over at Extreme Value Stocks fair-value is at 33.22

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Gertha, EVS, is a rear-view looking mechanism, and as such, presents a small window for evaluating a stock.

      For the forward looking investor that is; 5+ years, VRX is quite intriguing. I have a position in VRX, and a larger position in AGN -- the 800 LB gorilla -- leader in this sector.
      Allergan will be a big winner and represents the superior play; however, VRX will be a big winner too, by it's mere presence, size and offerings.
      There is room for VRX and other players in this sector.
      This is a win-win for both; AGN and VRX, in growing and expanding the depth and breadth of the aesthetic and dermatology markets.
      Competition doesn't have to be a win-lose proposition folks...
      This will be a huge upside for the BIG Players when they both flex their competitive marketing prowess; and it will be immediate!
      For the cognoscenti investor, this is like "double-barrel-pin-action" for the foreseeable future.

    • Who can anyone take a name like GerthaGertha, seriously..LOL Undervalued is more like it!!

      Sentiment: Strong Buy

182.32+2.72(+1.51%)Oct 2 4:01 PMEDT